Biogen: Kidney Diseases trials

The registry lists 14 Kidney Diseases studies with Biogen as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 3Phase 2 9Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA NephropathyCompletedNCT05065970Phase 2Results posted
• A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)CompletedNCT04702997Phase 2Results posted
• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)TerminatedNCT03749447Phase 3Results posted
• Phase II Study Assessing Safety and Efficacy of APL-2 in GlomerulopathiesCompletedNCT03453619Phase 2Results posted
• A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIXCompletedNCT03366337Phase 2Results posted
• Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)CompletedNCT04733040Phase 2
• A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal DialysisWithdrawnNCT01576887Phase 2
• Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 DiabetesWithdrawnNCT01551446Phase 1
• Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 DiabetesTerminatedNCT01549769Phase 1
• A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 DiabetesTerminatedNCT01500798Phase 1
• Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 DiabetesTerminatedNCT01351675Phase 3
• Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney DiseaseCompletedNCT01053936Phase 2
• Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney DiseaseCompletedNCT00811889Phase 2
• Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic NephropathyCompletedNCT00664027Phase 2